CURRICULUM VITAE:

PD Dr. Patricia Grabowski

Geb. 29.07.1969, Berlin, Germany, 3 children (6,9 16 years old)

Current working address:
Institut für Med. Immunologie
Charité-CVK, CC12, Föhrer Str. 15, 13353 Berlin &
Medizinische Klinik I,
Charité-CBF, AG-Grabowski, Hindenburgdamm 30, 12200 Berlin
Email: patricia.grabowski@charite.de
http://rcis.charite.de/forschung/forschungsgruppen_nutzer/ag_grabowski/

Education and Career:

1975 – 1979	St. Ursula-Grundschule, Berlin
1979 – 1988	Canisius-Kolleg, Gymnasium, Berlin, German Abitur; Mark: 1,1
1988-1990	Grant/Member: Studienstiftung des Deutschen Volkes
1988 – 1995	Medical School; Free University Berlin, Germany
1995 – 1996	Final year program: Charité Berlin, Germany; USCD Medical Center, San Diego, USA
1995	USMLE Part II
1996	German Final Exam (3. Staatsexamen) and licence to practice medicine
06/1996 – 11/2000	Junior / Residency (Internal Medicine), Medical Clinic, Gastroenterology, University Hospital Benjamin Franklin, Berlin, Germany
08/2002 – 01/2003	Postdoctoral fellowship (Molecular Biology), Charité, Campus Berlin-Buch, Klinik für Hämatologie/ Onkologie / Tumorimmunologie, Germany
12/2004 – 08/2007	Residency II (Internal Medicine), Medical Clinic, Gastroenterology, University Hospital Benjamin Franklin, Berlin, Germany
05/2007	Board examination “German Facharzt”, Internal Medicine
08/2011	Palliative Care Specialist (Palliative Care Medicine) Medical University of Jena, Germany
12/2015	Board examination “Subspecialization”, Hematology-Oncology

Positions and Employment:

05/2006 – ongoing	Lab Leader AG Grabowski at Charité, Campus Benjamin Franklin, Medizinische Klinik I, CC13, „Host Scientist“ at the Charité between 2007 and 2013
07/2007 – 09/2008	Attending at the Department of Gastroenterology, Endocrinology, Oncology, Head of the Department: Prof. Dr. D. Hörsch, Zentralklinik Bad Berka, Bad Berka, Germany

11/2009 – 10/2010	Senior Attending at the Department of Oncology, Head of the Department: Dr. R. Kobes-Schrödel, Median-Klinik II Bad Berka, Bad Berka, Germany
11/2010 – ongoing	Senior Attending at the Department of internal Oncology and Hematology, Head of the Department: Dr. C.-P. Schneider, Zentralklinik Bad Berka, Bad Berka, Germany Member of the „ENETs Center of Excellence“, Zentrum für Neuroendokrine Tumore Bad Berka, Bad Berka, Germany
09/2012 – 04/2013	Training in Hematology/Oncology Subspecialization in a private practice (Dr. Kühn, Berlin)
05/2013 – ongoing	Scientific Research Associate at the Institute of Medical Immunology, Charité- Berlin, CC12, Head of the Department: Prof. Dr. Volk (part-time position)

University Career/Teachings

1991 – 1994	Teaching Assistent at Institut für Molekularbiologie und Biochemie der FU Berlin
1997	Doctoral Thesis: „Identifizierung und Charakterisierung des Hepatom-assoziierten Glykoproteins hgp 115“. Dissertation, magna cum laude, Freie Universität Berlin; Supervisor: Prof. Dr. W. Reutter
12 July 2010	Habilitation und Venia legendi für das Fach Innere Medizin an der Charité – Universitätsmedizin Berlin Habilitationsschrift: „Innovative Ansätze in der Diagnostik und Therapie gastrointestinaler Tumore: Apoptose- und Zellzyklus-regulierende Proteine und ihre Bedeutung“; Supervisor: Prof. Dr. M. Zeitz

Further Qualifications

2006	„Zertifikat onkologische Gastroenterologie“ der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS)
September 2014	Qualification: Fachgebundene genetische Beratung nach dem Gendiagnostikgesetz

Research Support

09/2001-12/2003	Habilitationsstipendium des Berliner Senats/Kommission zur Förderung von Nachwuchswissenschaftlerinnen (KFN) der FU Berlin to P. Grabowski
05/2006-05/2007	Ernst von Leyden-Stipendium der Berliner Krebsgesellschaft to Inna Georgieva (9.000 Euro per year)
2006	Sonnenfeld-Stiftung: multiples devices (13.000 Euro). Project: Survivin: Bedeutung für Wachstum, Apoptose, Zellzyklusregulation von neuroendokrinen gastroenteropankreatischen Tumoren
06/2007-10/2007	Promotionsstipendium des DAAD to Inna Georgieva (715 Euro/month)
11/2007-03/2008	Abschlußstipendium der Sonnenfeld-Stiftung Berlin to Inna Georgieva (1000 Euro/month)

2009	Lydia-Rabinowitsch-Stip. of the Charité to P. Grabowski (10.075 Euro)
12/2011 – ongoing	DINSE-Foundation/Theranostics Research Network: "Forkheadbox proteins as target in GEP-NEN"; (2012: 38.000 Euro; 2013: 81.400 Euro; 2014: 71.340 Euro; 2015: 10.000 Euro; 2016: 15.000 Euro)
2012	Lydia-Rabinowitsch-Stip. of the Charité to P. Grabowski (8.000 Euro)
08/2012 – 07/2014	Ipsen-Pharma: "Investigation of the signaling network in GEP-NENs" (30.000 Euro)
07/2013 – 02/2016	Sonnenfeld-Stiftung Berlin: "Signalling pathways in GEP-NENs"; Grant to Dipl. Pharm. Helma Freitag (1000 Euro per month)
12/2013 – 11/2015	Novartis-Pharma: "Survivin as biomarker in GEP-NEN"; (22.400 Euro)
01/2015 – 12/2015	Novartis-Pharma: Start-up Grant for the Establishment of a German-wide pre-clinical network in neuroendocrine tumor research (Role: Organisator, Coordinator of the project, 14.000 Euro)
06/2015 – 06/2017	Rhön RKA Förderpool: "Predictive biomarkers for a personalized therapy of advanced pancreatic neuroendocrine tumours (PREDICT) – ENETS Center Marburg and Bad Berka (Role: Coordinator of the project, 80.000 Euro)
06/2015 - 06/2017	Rhön RKA Förderpool: "Imaging chemokine receptor (CCL2-CCR2) signaling to improve lung cancer diagnosis and therapy" – ENETS Center Gießen and Bad Berka (Role: Cooperate partner, 25.000 Euro)
06/2015 – 12/2016	Ipsen-Pharma: "Lanreotide in bronchial NENs" (20.000 Euro)
04/2015 – 03/2016	Berliner Krebsgesellschaft Grant to P. Grabowski and A. Busse Project: "Tumor microenvironment of low and high grade GEP-NENs: Identification of targets for immune modulation and definition of prognostic and predictive immune parameters" (40.000 Euro)
04/2015	Sonnenfeld-Stiftung: Tape Station (devise) for measurement of RNA and DNA (18.000 Euro)
2016	Lydia-Rabinowitsch-Stip. of the Charité to I. Georgieva (4.400 Euro)
05/2016- 04/2017	Berliner Krebsgesellschaft Grant (1/4 position to P. Grabowski) Project: Aufbau einer Tumor-Fatigue-Sprechstunde an der Charité (28.000 Euro)

Publication list

M. Loebel, M. Eckey, E. Hahn, S. Bauer, **P. Grabowski**, J. Zerweck, P. Holenya, L.G. Hanitsch, K. Wittke, P. Borchmann, J.U. Rüffer, F. Hiepe, K. Ruprecht, H.D. Volk, U. Reimer, C. Scheibenbogen **(2016)**
„Serological profiling of the EBV immune response in Chronic Fatigue Syndrome using a peptide microarray"
PLoSOne, submitted

L.G. Hanitsch, M. Löbel, J.F. Mieves, S. Bauer, N. Babel, B. Schweiger, K. Wittke, **P. Grabowski**, H.D. Volk, C. Scheibenbogen **(2016)**
„Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency"

Vaccine, 5;34(21):2417-23.

F. Briest; I. Grass; M. Mobs; F. Christen; S. Mende; D. Kaemmerer; H. Freitag; F. Lewens; S. Iwazkiewicz; J. Sanger; A. Kunze; B. Siegmund; M. Hummel; **P. Grabowski (2016)**
"Targeting the MDM2-p53-FOXM1 axis re-induces antiproliferative signaling, downregulates FOXM1 effector genes and synergizes with cisplatin and bortezomib in p53 wild type gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)"
Endocrine related cancer, in revision 11/2016

F. Lewens; F. Briest; R. Arsenic; J. Sänger; A. Kunze; M. Möbs; H. Freitag; F. Christen; D. Kämmerer; A. Lupp; M. Heilmann; C.P. Schneider, K. Richter; M. Hummel; B. Siegmund; **P. Grabowski (2016)**
The pro-proliferative protein FOXM1 serves as clinical marker and potential target in bronchopulmonary neuroendocrine cancer. *Oncotarget,* in revision 10/2016

C. Treese; P. Sanchez; **P. Grabowski**; E. Berg; H. Bläker; M. Kruschewski; O, Haase; M. Hummel; S. Daum **(2016)**
Poorly differentiated medullary phenotype predicts poor survival in early lymph node-negative gastro-esophageal adenocarcinomas. *PLoSOne, in press*

H. Freitag; F. Christen; F. Lewens; I. Grass; F. Briest; S. Iwaszkiewicz; B. Siegmund; **P. Grabowski (2016)**
"Dual inhibition of PI3K and mTORC1/C2 by PKI-587 (PF-05212384) as a promising therapeutic option for gastroenteropancreatic neuroendocrine tumor disease and its effect on AKT-Signaling"
Neuroendocrinology 2016 Aug 12. [Epub ahead of print]

M. Löbel, **P. Grabowski,** H. Heidecke, S. Bauer, LG Hanitsch, K. Wittke, C. Meisel, P. Reinke, HD Volk, O. Fluge, O. Mella, C. Scheibenbogen **(2016)**
"Antibodies to ß adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome"
Brain, Behavior, and Immunity, 52:32-9.

P. Grabowski, D. Hörsch **(2015)**
Leitlinien für gastroenteropankreatische neuroendokrine Tumoren – was ist neu ? Was sollte in die Therapierichtlinien aufgenommen werden ?
Zeitschrift für Gastroenterologie, 53(10):1194-200.

S. Guenther; M. Loebel; A.A. Mooslechner; M. Knops; L.G. Hanitsch; **P. Grabowski**; K. Wittke; C. Meisel; N. Unterwalder; HD Volk; C. Scheibenbogen **(2015)**
"Frequent IgG subclass and mannose binding lectin deficiency in patients with Chronic Fatigue Syndrome" has been accepted for publication in Human Immunology"
Human Immunology, 76(10):729-35.

M. Löbel, AA Mooslechner, S. Bauer, S. Guenther, A. Letsch, LG Hanitsch, **P. Grabowski**, C. Meisel, HD Volk, C. Scheibenbogen **(2015)**
"Polymorphism in COMT is associated with IgG subclass levels and susceptibility to infection in patients with Chronic Fatigue Syndrome"
Journal of Translational Medicine, 13:264

F. Briest, E. Berg, H. Freitag, D.Kämmerer, I. Grass, F. Lewens, F. Christen, R. Arsenic, A. Altendorf-Hofmann, A. Kunze, J. Sänger, T. Knösel, B. Siegmund, M. Hummel, **P. Grabowski (2015)**
FOXM1 is a novel drug target in gastroenteropancreatic neuroendocrine tumor disease.
Oncotarget, 6(10):8185-99.
F. Briest, **P. Grabowski** (**2015)**
The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms.
Cancer Treat Rev. 41(5):423-30. Review

F. Briest, **P. Grabowski** (**2014**)
„PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms.
Theranostics, 4(4):336-365. Review

C. Scheibenbogen, HD Volk, **P. Grabowski**, K. Wittke, B. Hoffmeister, L. Hanitsch **(2014)**
„Chronisches Fatigue-Syndrom: Heutige Vorstellungen zur Pathogenese, Diagnostik und Therapie“
Tägliche Praxis, 55: 567-574. Review

P. Grabowski, F. Briest, RP. Baum, JJ Zaknun, HR Kulkarni, M. Zeitz, D. Hörsch **(2012)**
“Vandetanib therapy in medullary thyroid cancer”.
Drugs Today (Barc), 48(11):723-33. Review

D. Hörsch, **P. Grabowski** , CP Schneider, A. Petrovitch, M. Hommann, D. Kaemmerer, RP Baum **(2011)**
„Current treatment options for neuroendocrine tumors“ *Drugs Today (Barc),* 47(10):773-86. Review

N. Posorski, D. Kaemmerer, G. Ernst, **P. Grabowski**, D. Hörsch, M. Hommann, F. von Eggeling **(2011)**
“Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases”.
Clinical & Experimental Metastasis, 28(7):637-47

I. Georgieva, D. Koychev, Y. Wang, J. Holstein, W. Hopfenmüller, M. Zeitz, **P. Grabowski (2010)**
“ZM 447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and pro-apoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines”
Neuroendocrinology, 91(2):121-130

S. Lorenzen, T. Schuster, R. Porschen, S.E. Al-Batran, R. Hofheinz, P Thuss-Patience, M. Moehler, **P. Grabowski**, D. Arnold, T. Greten, L. Müller, N. Röthling, C. Peschel, R. Langer, F. Lordick **(2009)**
„Cetuximab plus cisplatin-5-fuorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a radomized phase II study of the ArbeitsgemeinschaftInternistischeOnkologie“
Annals of Oncology, 10:1667-73

P. Grabowski, J. Schrader, J. Wagner, D. Hörsch, R. Arnold, C.N. Arnold, I. Georgieva, H. Stein, M. Zeitz, PT Daniel, I. Sturm **(2008)**
“Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors”
Clinical Cancer Research, 14: 7378-734

CN Arnold, T. Nagasaka, A. Goel, I. Scharf, **P. Grabowski**, A. Sosnowski, A. Schmitt-Gräf, CR Boland, R. Arnold, HE Blum **(2008)**
„Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors“
International Journal of Cancer 123(7):1556-64

P. Kiewe, M. Tepel, C. Loddenkemper, M. Grünbaum, **P. Grabowski**, A. Korfel, E. Thiel **(2007)**
„Extensic leukemic kidney infiltration with membranoproliferative glomerulonephritis in a patient with B-cell chronic lymphocytic leukemia”
Annals of Hematology 86(9):691-2

P. Grabowski, S. Daum, B. Heine, M. Kruschewski, M. Zeitz, J.C. Hoffmann **(2006)**
„An unusual case of upper GI bleeding: Esophageal cancer metastasis at percutaneous endoscopic gastrostomy site“
Zeitschrift für Gastroenterologie 44(11):1145-1149

P. Grabowski, AP Sutter, H. Scherübl **(2006)**
„Molekulare Regulation neuroendokriner Tumoren des Gastrointestinaltraktes.“
In: Ganten D (Hrsg.), Molekularmedizinische Grundlagen von Endokrinopathien 2 – Para- und autokrine Regulation. Springer Verlag, Heidelberg.

P. Grabowski, I. Sturm, K.Schelwies, K. Maaser, H.-J. Buhr, M. Zeitz, B. Dörken, P.T. Daniel, H. Scherübl **(2006)**
“Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis” *International Journal of Colorectal Disease, 21:221-230*

P. Grabowski*, K. Maaser*, C. Hanski, H. Stein, I. Sturm, W. Hopfenmüller, B. Dörken, HJ Buhr, M. Zeitz, H. Scherübl **(2005)**
„Prognostic value of multimarker analysis in stage III colorectal cancer: one step forward towards an individualized therapy decision"
Onkologie, 28: 399-403 (*Dual first-authorship)

P. Grabowski, H. Scherübl **(2005)**
"Neuroendocrine differentiation of small-cell carcinomas of the gastrointestinal tract"
Journal of Clinical Oncology, 23:4795-6 author reply

P. Grabowski, S. Griß, C.N. Arnold, D. Hörsch, R. Göke, R. Arnold, B. Heine, H. Stein, M. Zeitz , H. Scherübl **(2005)**
"Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease"
Neuroendocrinology, 81:1-9

K. Maaser*, **P. Grabowski***, Y. Özdem, A. Krahn, B. Heine, HJ Buhr, M. Zeitz, H. Stein, H. Scherübl **(2005)**
"Up-regulation of the peripheral benzodiazepine receptor during human colorectal carcinogenesis and tumor spread"
Clinical Cancer Research, 11:1751-1756 (*Dual first-authorship)

P. Grabowski, J. Schönfelder, G. Ahnert-Hilger, HD Foss, H. Stein, G. Berger, M. Zeitz, H. Scherübl **(2004)**
"Heterogenous expression of neuroendocrine marker proteins in human undifferentiated carcinoma of the colon and rectum"
Annals of the New York Academy of Sciences, 1014: 270-274

AP Sutter, K. Maaser, **P. Grabowski**, G. Bradacs, K. Vormbrock, M. Höpfner, A. Krahn, B. Heine, H. Stein, R. Soma-sundaram, D. Schuppan, M. Zeitz, H. Scherübl **(2004)**
"Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA 14-1". *Journal of Hepatology, 41: 799-807*

K. Maaser, AP Sutter, A. Krahn, M. Höpfner, **P. Grabowski**, H. Scherübl **(2004)**
"Cell cycle-related signaling pathways modulated by peripheral benzodiazepine receptor ligands in colorectal cancer cells"
Biochemical and Biophysical Research Communications, 324: 878-886

P. Grabowski, T. Kühnel, F. Mühr-Wilkenshoff, B. Heine, H. Stein, M. Höpfner, CT Germer, M. Zeitz, H. Scherübl **(2003)**
"Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma"
British Journal of Cancer, 88(1): 115-119

H. Scherübl, **P. Grabowski (2003)**
"The chromogranin-secretonin family"
New England Journal of Medicine, 348 (25): 2579-80 author reply

P. Grabowski, H. Scherübl **(2003)**
"Survivin - an anti-apoptosis protein"
Medical Science Monitor 9(11): LE25

K. Schelwies, I. Sturm, **P. Grabowski**, H. Scherübl, I. Schindler, S. Hermann, H. Stein, HJ Buhr, EO Riecken, M. Zeitz, B. Dörken, PT Daniel **(2002)**
"Low bax protein expression is a negative prognostic factor in primary colorectal cancer"
International Journal of Cancer, 99: 589-596

P. Grabowski, J. Schönfelder, G. Ahnert-Hilger, HD Foss, B. Heine, I. Schindler, H. Stein, G. Berger, M. Zeitz, H. Scherübl **(2002)**
"Expression of neuroendocrine markers: A signature of human undifferentiated carcinoma of the colon and rectum"
Virchows Archiv, 441(3): 256-263

AP Sutter, K. Maaser, M. Höpfner, B. Barthel, **P. Grabowski**, S. Faiss, P. Carayon, M. Zeitz, H. Scherübl **(2002)**
"Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human oesopha-geal cancer cells"
International Journal of Cancer, 102(4): 318-327

K. Maaser*, **P. Grabowski***, I. Schindler, H.D. Foss, H. Stein, P. Carayon, M. Gavish, EO Riecken, M. Zeitz, H. Scherübl **(2002)**

"Overexpression of the peripheral-type benzodiazepine receptor is a relevant prognostic factor in stage III colorectal cancer" *Clinical Cancer Research, 8 (10): 3205-3209* (*Dual first-authorship)

K. Lemmer, G. Ahnert-Hilger, M. Höpfner, S. Hoegerle, S. Faiss, **P. Grabowski**, M. Jockers-Scherübl, EO Riecken, M. Zeitz, H. Scherübl **(2002)**
"Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells"
Life Sciences, 72: 667-678

P. Grabowski, I. Schindler, I. Anagnostopoulos, HD Foss, EO Riecken, U. Mansmann, H. Stein, G. Berger, HJ Buhr, H. Scherübl **(2001)**
"Neuroendocrine differentiation is a relevant prognostic factor in stage III-IV colorectal cancer"
European Journal of Gastroenterology and Hepatology, 13: 405-411

P. Grabowski, B. Mann, U. Mansmann, N. Lövin, HD Foss, G. Berger, H. Scherübl, EO Riecken, HJ Buhr, C. Hanski **(2000)**
"Expression of sialyl-Le^x antigen defined by MAb AM-3 is an independent prognostic marker in colorectal carcinoma patients"
International Journal of Cancer, 88: 281-286

Selected Poster and Talks:

Y. Wang, F. Briest, S. Greshake, A. Lock, D. Hörsch, C. Arnold, E.Berg, M. Hummel, B. Siegmund, **P. Grabowski**
"Immunohistochemical study of AuroraB proves association with differentiation and expression of crucial progression markers in gastroenteropancreatic neuroendocrine neoplasms"
D.A.C.H. und ECE Tagung, München 2016. Poster

F. Christen, I. Grass, L. Worpenberg, F. Lewens, F. Briest, B. Siegmund, **P. Grabowski**
"FOXM1 as chemo-sensitizing target in neuroendocrine lung tumors"
D.A.C.H. und ECE Tagung, München 2016. Poster

V. Bröker, H. Freitag, F. Christen, F. Briest, B. Siegmund, **P. Grabowski**
"Dual Inhibition of PI3K and mTORC1/C2 by PKI-587 (PF-05212384) as a Promising Therapeutic Option for Pulmonary Neuroendocrine Tumor Disease"
D.A.C.H. und ECE Tagung, München 2016. Poster

F. Jost-Brinkmann, F. Briest, D. Sedding, F. Lewens, B. Siegmund, **P. Grabowski**
„Antiproliferative effects of Lanreotide in neuroendocrine lung tumor cell lines"
D.A.C.H. und ECE Tagung, München 2016. Poster

P. Grabowski
„Aktueller Stand und Fortschritte der AG NET"
Frühjahrstagung des NET-Registers, D.A.C.H. Tagung, München 2016. Vortrag

Briest F, Christen F, Worpenberg L, Welzel M, Freitag H, Fischer C, **Grabowski P.**
"The Proteasome Inhibitor Bortezomib is a highly effective Treatment Option for Gastroenteropancreatic Neuroendocrine Neoplasms and sensitizes to DNA damaging Therapy in vitro."
ENETS conference 2016, Barcelona, Spain. Poster

Briest F*, Grass I*, Siegmund B, **Grabowski P**.
"The CDK4/6 Inhibitor Palbociclib induces anti-proliferative Mechanisms in Gastroenteropancreatic Neuroendocrine Neoplasms in vitro. "
ENETS conference 2016, Barcelona, Spain. Poster

Lock A, Wirtz R, Kaemmerer D, Haugvik S P, Kure E, Buchholz M, Gress T, Arsenic R, Briest F, Siegmund B, Hörsch D, **Grabowski P.**
"Is mTOR pathway activity a good predictor for Everolimus therapy? A pilot study to build up a Phase II trial in pancreatic neuroendocrine neoplasias (pNENs)."
ENETS conference 2016, Barcelona, Spain. Poster

Nölting S, Rentsch J, Freitag H, Briest F, Schrader J, König A, Aristizabal Prada ET, Siegmund B, Auernhammer CJ, **Grabowski P.**

"Selective Inhibition of PI3Kalpha (BYL719) - Promising Therapeutic Option for neuroendocrine tumors?"
ENETS conference 2016, Barcelona, Spain. Poster

Briest F, **Grabowski P.**
"DNA damage response as chemotherapy-sensitizing therapeutic target in neuroendocrine tumors: preclinical studies and translational perspectives."
Neuroendocrine Tumors Scientific Exchange Meeting 2016, Rome, Italy. Vortrag

Spenke C, Jöhrens K, Arsenic R, Briest F, Lammert H, Kaemmerer D, Hummel M, Scheibenbogen C, Busse A*, **Grabowski P***.
"Tumor infiltrating lymphocytes and PD-1/PD-L1 expression differ between low and high grade neuroendocrine tumors – first results of a protein- and array-based pilot study."
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie (DGHO). 2015, Basel, Switzerland. Poster

Grabowski, P.
„Tumor infiltrating lymphocytes and PD-L1 expression differ in low and high grade neuroendocrine tumors" (ENETS No 1199)
ENETS conference 2015, Barcelona, Spain. Vortrag

Briest F, **Grabowski P.**
"From Bench to bedside - Emerging Targets in NEN".
INKEP Meeting 2015, Bad Berka, Germany. Vortrag